Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dl-amphetamine Sulfate
2. Amphetamine Sulphate
3. Phenaminum
4. 60-13-9
5. Amphamine Sulfate
6. Amphetamini Sulfas
7. Dl-phenamine Sulfate
8. Dl-amphetamine Sulphate
9. Amphetaminium Sulfuricum
10. Desoxynorephedrine Sulfate
11. (+-)-amphetamine Sulfate
12. Dl-amphetamine Hydrogen Sulfate
13. (+-)-phenisopropylamine Sulfate
14. Amfetamine Sulfate
15. Amphetamine Sulfate [usp]
16. Dl-1-phenyl-2-aminopropane Sulfate
17. (+-)-2-amino-1-phenylpropane Sulfate
18. (+-)-alpha-methylphenethylamine Sulfate (2:1)
19. 6dpv8nk46s
20. 1-phenylpropan-2-amine Sulfate (2:1)
21. Amphetamine Sulfate (usp)
22. Fenopromin Sulfate
23. Penamine (van)
24. Ccris 3644
25. 1-phenyl-2-aminopropane Sulfate
26. Cerm 1767
27. Razemisches Phenylaminopropansulfat
28. Dl-alpha-methylphenethylamine Sulfate
29. Einecs 200-457-8
30. Unii-6dpv8nk46s
31. Nsc 170999
32. Dl-amphetamine Sulfate Salt
33. Benzadrine
34. Alpha-methylphenethylamine Sulfate, (+-)-
35. Benzedrine (tn)
36. Evekeo (tn)
37. Evekeo Odt
38. Rac-amphetamine Sulphate
39. D-amphetamine Sulfate Salt
40. Schembl41204
41. Amphetamine Sulfate [mi]
42. Dtxsid4020082
43. Phenethylamine, Alpha-methyl-, Sulfate (2:1), (+-)-
44. Chebi:51063
45. Amfetamine Sulfate [mart.]
46. Amphetamine Sulfate [vandf]
47. Amfetamine Sulfate [who-dd]
48. Bis{1-phenylpropan-2-amine} Sulfate
49. Amfetamine Sulfate [ep Impurity]
50. Amfetamine Sulfate [ep Monograph]
51. Amphetamine Sulfate [orange Book]
52. .beta.-phenylisopyropylaminesulfate
53. Benzeneethanamine, Alpha-methyl-, Sulfate
54. Amphetamine Sulfate [usp Monograph]
55. Amfetamine Sulfate [incb:green List]
56. Delcobese Component Amphetamine Sulfate
57. D02074
58. (+/-)-2-amino-1-phenylpropane Sulfate
59. (+/-)-2-amino-1-phenylpropane Sulphate
60. Amphetamine Sulfate Component Of Delcobese
61. Q21270844
62. (+/-)-.alpha.-methylphenethylamine Sulfate (2:1)
63. (+/-)-.alpha.-methylphenethylamine Sulphate (2:1)
64. Benzeneethanamine, .alpha.-methyl-, Sulfate (2:1), (+/-)-
65. Benzeneethanamine, .alpha.-methyl-, Sulphate (2:1), (+/-)-
66. Dl-amphetamine Sulfate Salt Solution, Drug Standard, 1.0 Mg/ml In Methanol
67. 2-(tetrahydro-furan-2-yl)-n-(3-trifluoromethyl-phenyl)-succinamicacid
68. 156-31-0
1. Amfetamine
2. Mydrial
3. Desoxynorephedrine
4. L Amphetamine
Molecular Weight | 368.5 g/mol |
---|---|
Molecular Formula | C18H28N2O4S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 368.17697855 g/mol |
Monoisotopic Mass | 368.17697855 g/mol |
Topological Polar Surface Area | 135 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 166 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15089
Submission : 2000-10-13
Status : Active
Type : II
NDC Package Code : 49812-0059
Start Marketing Date : 1999-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : CA |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14783
Submission : 2000-03-17
Status : Active
Type : II
NDC Package Code : 49812-0058
Start Marketing Date : 1999-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : CA |
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-10
Pay. Date : 2013-04-03
DMF Number : 23583
Submission : 2010-03-04
Status : Active
Type : II
Available Reg Filing : CA |
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-10
Pay. Date : 2013-04-03
DMF Number : 24048
Submission : 2010-07-08
Status : Active
Type : II
Available Reg Filing : CA |
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-08-04
Pay. Date : 2015-08-27
DMF Number : 29601
Submission : 2016-02-25
Status : Active
Type : II
NDC Package Code : 0792-3939
Start Marketing Date : 2023-11-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-05-24
Pay. Date : 2015-08-27
DMF Number : 29604
Submission : 2016-02-25
Status : Active
Type : II
NDC Package Code : 0792-3936
Start Marketing Date : 2022-12-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-22
Pay. Date : 2023-11-03
DMF Number : 38836
Submission : 2023-10-20
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-17
Pay. Date : 2013-03-11
DMF Number : 15385
Submission : 2001-04-18
Status : Active
Type : II
Certificate Number : R0-CEP 2020-076 - Rev 00
Issue Date : 2021-07-26
Type : Chemical
Substance Number : 2752
Status : Valid
NDC Package Code : 0406-4942
Start Marketing Date : 2013-11-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-08
Pay. Date : 2013-05-31
DMF Number : 15425
Submission : 2001-05-09
Status : Active
Type : II
NDC Package Code : 0406-1950
Start Marketing Date : 2013-04-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5378
Submission : 1984-02-09
Status : Inactive
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 190
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 190
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 190
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 215
2019 Revenue in Millions : 194
Growth (%) : 11
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 215
2019 Revenue in Millions : 194
Growth (%) : 11
Amphetamine, Dextroamphetamine Sulfate, Dextroamphetami...
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 215
2019 Revenue in Millions : 194
Growth (%) : 11
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 171
2020 Revenue in Millions : 207
Growth (%) : -11
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 171
2020 Revenue in Millions : 207
Growth (%) : -11
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 171
2020 Revenue in Millions : 207
Growth (%) : -11
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 184
2021 Revenue in Millions : 171
Growth (%) : 8
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
81
PharmaCompass offers a list of Amphetamine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Amphetamine manufacturer or Amphetamine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Amphetamine manufacturer or Amphetamine supplier.
PharmaCompass also assists you with knowing the Amphetamine API Price utilized in the formulation of products. Amphetamine API Price is not always fixed or binding as the Amphetamine Price is obtained through a variety of data sources. The Amphetamine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dexamphetamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dexamphetamine, including repackagers and relabelers. The FDA regulates Dexamphetamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dexamphetamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dexamphetamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dexamphetamine supplier is an individual or a company that provides Dexamphetamine active pharmaceutical ingredient (API) or Dexamphetamine finished formulations upon request. The Dexamphetamine suppliers may include Dexamphetamine API manufacturers, exporters, distributors and traders.
click here to find a list of Dexamphetamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dexamphetamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Dexamphetamine active pharmaceutical ingredient (API) in detail. Different forms of Dexamphetamine DMFs exist exist since differing nations have different regulations, such as Dexamphetamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dexamphetamine DMF submitted to regulatory agencies in the US is known as a USDMF. Dexamphetamine USDMF includes data on Dexamphetamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dexamphetamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dexamphetamine suppliers with USDMF on PharmaCompass.
A Dexamphetamine CEP of the European Pharmacopoeia monograph is often referred to as a Dexamphetamine Certificate of Suitability (COS). The purpose of a Dexamphetamine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dexamphetamine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dexamphetamine to their clients by showing that a Dexamphetamine CEP has been issued for it. The manufacturer submits a Dexamphetamine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dexamphetamine CEP holder for the record. Additionally, the data presented in the Dexamphetamine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dexamphetamine DMF.
A Dexamphetamine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dexamphetamine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dexamphetamine suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dexamphetamine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dexamphetamine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dexamphetamine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dexamphetamine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dexamphetamine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dexamphetamine suppliers with NDC on PharmaCompass.
Dexamphetamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dexamphetamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dexamphetamine GMP manufacturer or Dexamphetamine GMP API supplier for your needs.
A Dexamphetamine CoA (Certificate of Analysis) is a formal document that attests to Dexamphetamine's compliance with Dexamphetamine specifications and serves as a tool for batch-level quality control.
Dexamphetamine CoA mostly includes findings from lab analyses of a specific batch. For each Dexamphetamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dexamphetamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Dexamphetamine EP), Dexamphetamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dexamphetamine USP).